companies making glp-1 drugs Agonists Market Report 2025-2033, By Product, Molecule, and Geo America's Poison Centers - GLP-1

[DOI] [PMC free article] [PubMed] [Google Scholar] 54.McClean P

In practical terms, that means the typical individual in Mississippi would need to spend roughly one-eighth of their annual income to maintain continuous GLP-1 treatment, a cost so steep it would likely require cutting back on essentials or major lifestyle expenses just to afford it

In the field of obesity medicine, we often focus on the metabolic and cardiovascular "bonuses," but the potential for neuroprotection, specifically by reducing neuroinflammation and improving brain insulin sensitivity adds an entirely new dimension to how we view these molecules

Complications can include severe dehydration, malnutrition, and unpredictable blood sugar levels, which are particularly dangerous for diabetic patients